摘要
目的:探讨硝苯地平缓释剂对原发性高血压病(EH)患者内皮素(ET)和降钙素基因相关肽(CGRP)含量变化及氨氯地平对其影响。方法:回顾性分析2005年9月～2009年12月收治入院的60例原发性高血压病患者,观察治疗后患者疗效及其治疗前后ET和CGRP含量变化。结果:硝苯地平缓释剂治疗EH患者白昼及夜间血压下降,治疗后EH患者血浆ET水平降低,而CGRP明显升高。结论:ET及CGRP参与了EH的病理过程,硝苯地平缓释剂是一种治疗患者有效药物,能纠正患者ET与CGRP之间的失衡。
Objective： To explore influence of Nifedipine Sustained Release Tablets on essential hypertension （EH） Endothelin （ET） and calcitonin gene-related peptidc （CGRP） content and the impact of Amlodipine. Methods： 60 patients with primary hypertension admitted to hospital from September 2005 to December 2009 were retrospective analysed, ET and CGRP content were observed before and after treatment. Results： The day and nighttime blood pressure of patients with essential hypertension droped, the level of plasma ET reduced, CGRP significantly increased after treatment. Conclusion： ET and CGRP participate in the pathogenesis of EH, Nifedipine Sustained Release Tablets is an effective drug for the treatment Of patients with EH to correct the imbalance between ET and CGRP.
出处
《中国医药导报》
CAS
2011年第7期66-67,共2页
China Medical Herald
